trastuzumab emtansine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
humanized origin	4990	1018448-65-1

Description:

Molecule	Description
Synonyms: trastuzumab-DM1 conjugate trastuzumab emtansine ado-trastuzumab emtansine kadcyla PRO132365 trastuzumab-MCC-DM1 T-DM1 huN901-DM1	Immunotoxin that consists of humanized monoclonal anti-HER2 antibody TRASTUZUMAB covalently linked to anti-microtubule agent MAYTANSINOID DM1 for treatment of metastatic breast cancer in patients who previously received trastuzumab and a TAXANES, separately or in combination. Molecular weight: Formula: (C47H62ClN4O14S)3-4 CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

trastuzumab-DM1 conjugate
trastuzumab emtansine
ado-trastuzumab emtansine
kadcyla
PRO132365
trastuzumab-MCC-DM1
T-DM1
huN901-DM1

Immunotoxin that consists of humanized monoclonal anti-HER2 antibody TRASTUZUMAB covalently linked to anti-microtubule agent MAYTANSINOID DM1 for treatment of metastatic breast cancer in patients who previously received trastuzumab and a TAXANES, separately or in combination.

Molecular weight:
Formula: (C47H62ClN4O14S)3-4
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company
Nov. 15, 2013	EMA
Feb. 22, 2013	FDA	GENENTECH
Sept. 20, 2013	PMDA	Chugai Pharmaceutical Co., Ltd

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Disease progression	684.47	22.40	451	20298	122307	63345966
Metastases to central nervous system	539.48	22.40	191	20558	12914	63455359
Neuropathy peripheral	316.05	22.40	276	20473	113391	63354882
Ejection fraction decreased	305.19	22.40	148	20601	22184	63446089
Platelet count decreased	295.10	22.40	268	20481	115854	63352419
Thrombocytopenia	292.07	22.40	300	20449	150857	63317416
Epistaxis	186.79	22.40	169	20580	72556	63395717
Metastases to lymph nodes	178.06	22.40	75	20674	8083	63460190
Metastases to lung	160.70	22.40	80	20669	12670	63455603
Nodular regenerative hyperplasia	131.43	22.40	31	20718	475	63467798
Palmar-plantar erythrodysaesthesia syndrome	131.22	22.40	86	20663	22929	63445344
Radiation necrosis	127.52	22.40	29	20720	375	63467898
Malignant neoplasm progression	126.78	22.40	145	20604	81976	63386297
Metastases to bone	118.50	22.40	78	20671	20941	63447332
Myelosuppression	105.41	22.40	76	20673	23627	63444646
Metastases to skin	103.08	22.40	33	20716	1630	63466643
Cardiotoxicity	100.60	22.40	51	20698	8387	63459886
Portal hypertension	93.09	22.40	38	20711	3781	63464492
Neoplasm progression	90.20	22.40	83	20666	36345	63431928
Spider naevus	86.44	22.40	18	20731	149	63468124
Joint swelling	84.04	22.40	6	20743	327660	63140613
Blood lactate dehydrogenase increased	82.53	22.40	65	20684	23051	63445222
Metastases to liver	81.25	22.40	65	20684	23574	63444699
Aspartate aminotransferase increased	79.47	22.40	121	20628	90156	63378117
Excessive eye blinking	73.62	22.40	24	20725	1256	63467017
Pneumonitis	73.45	22.40	73	20676	35149	63433124
Metastasis	72.62	22.40	35	20714	5162	63463111
Blood uric acid decreased	71.35	22.40	21	20728	780	63467493
Left ventricular dysfunction	71.26	22.40	46	20703	11942	63456331
Drug hypersensitivity	70.94	22.40	9	20740	310678	63157595
Rheumatoid arthritis	70.15	22.40	3	20746	253816	63214457
Polyneuropathy	69.98	22.40	49	20700	14540	63453733
Alanine aminotransferase increased	69.58	22.40	123	20626	103647	63364626
Breast cancer recurrent	69.15	22.40	32	20717	4309	63463964
Breast cancer metastatic	66.28	22.40	44	20705	11974	63456299
Product dose omission issue	63.99	22.40	3	20746	234310	63233963
Axillary pain	63.35	22.40	24	20725	1959	63466314
Recurrent cancer	63.30	22.40	24	20725	1963	63466310
Eosinophil percentage increased	62.06	22.40	20	20729	1009	63467264
Vascular device infection	61.36	22.40	35	20714	7277	63460996
Hyperchlorhydria	57.76	22.40	22	20727	1822	63466451
Blood alkaline phosphatase increased	56.57	22.40	70	20679	42897	63425376
Abdominal discomfort	55.33	22.40	18	20731	320867	63147406
Constipation	54.98	22.40	180	20569	224763	63243510
Telangiectasia	54.60	22.40	18	20731	976	63467297
Pleural effusion	54.30	22.40	104	20645	93106	63375167
Hepatotoxicity	53.09	22.40	63	20686	36978	63431295
Systemic lupus erythematosus	53.03	22.40	4	20745	208914	63259359
Mucosal inflammation	51.69	22.40	70	20679	46858	63421415
Arthropathy	50.76	22.40	8	20741	234784	63233489
Blood creatinine decreased	50.48	22.40	28	20721	5517	63462756
Treatment failure	49.98	22.40	4	20745	199039	63269234
Diarrhoea	49.83	22.40	401	20348	714965	62753308
Drug interaction	49.10	22.40	8	20741	229123	63239150
Gamma-glutamyltransferase increased	48.96	22.40	58	20691	33973	63434300
Interstitial lung disease	48.93	22.40	79	20670	61829	63406444
Metastases to spine	48.81	22.40	23	20726	3226	63465047
Hypertransaminasaemia	48.50	22.40	29	20720	6580	63461693
Gingival bleeding	48.42	22.40	37	20712	12550	63455723
Non-cirrhotic portal hypertension	48.40	22.40	12	20737	229	63468044
Breast neoplasm	48.17	22.40	18	20731	1414	63466859
Peripheral sensory neuropathy	47.79	22.40	30	20719	7421	63460852
Dyschezia	46.44	22.40	20	20729	2274	63465999
Radiation pneumonitis	46.41	22.40	18	20731	1565	63466708
Asthenopia	46.08	22.40	20	20729	2317	63465956
Nail dystrophy	45.93	22.40	16	20733	1027	63467246
Ejection fraction	45.52	22.40	20	20729	2386	63465887
Vessel puncture site bruise	45.42	22.40	13	20736	437	63467836
Blood bilirubin increased	44.91	22.40	58	20691	37082	63431191
Breast disorder	44.55	22.40	20	20729	2510	63465763
Condition aggravated	44.06	22.40	40	20709	402177	63066096
Hepatic cirrhosis	43.86	22.40	47	20702	24687	63443586
Performance status decreased	43.17	22.40	22	20727	3656	63464617
Swelling	43.15	22.40	18	20731	275360	63192913
Tumour marker increased	42.52	22.40	24	20725	4891	63463382
Hypokalaemia	42.13	22.40	100	20649	103704	63364569
Haematotoxicity	41.52	22.40	30	20719	9346	63458927
Nausea	41.33	22.40	443	20306	854028	62614245
Neutropenia	40.90	22.40	138	20611	174867	63293406
Lymphangiosis carcinomatosa	40.84	22.40	16	20733	1429	63466844
Dry skin	38.83	22.40	68	20681	56819	63411454
Hypothalamo-pituitary disorder	38.82	22.40	13	20736	740	63467533
Folate deficiency	38.66	22.40	18	20731	2457	63465816
Sinusitis	38.54	22.40	13	20736	226640	63241633
Death	38.44	22.40	231	20518	374150	63094123
Brain oedema	38.38	22.40	34	20715	14161	63454112
Lacrimation increased	37.99	22.40	40	20709	20591	63447682
Discomfort	37.80	22.40	5	20744	167369	63300904
Carcinoembryonic antigen increased	37.75	22.40	16	20733	1749	63466524
Vulvovaginal candidiasis	37.29	22.40	19	20730	3156	63465117
Hiccups	37.27	22.40	17	20732	2214	63466059
Drug intolerance	37.12	22.40	28	20721	308633	63159640
Hyperbilirubinaemia	36.52	22.40	30	20719	11284	63456989
Pituitary tumour	35.89	22.40	13	20736	935	63467338
Eastern Cooperative Oncology Group performance status worsened	35.85	22.40	14	20735	1240	63467033
Cellulitis	35.49	22.40	81	20668	81877	63386396
Arteriovenous malformation	34.75	22.40	14	20735	1346	63466927
Injection site extravasation	34.03	22.40	26	20723	8815	63459458
Ascites	33.58	22.40	53	20696	40675	63427598
Hydrocephalus	33.14	22.40	21	20728	5279	63462994
Splenomegaly	32.74	22.40	28	20721	11129	63457144
Gastrointestinal toxicity	32.54	22.40	24	20725	7717	63460556
Decreased appetite	32.49	22.40	165	20584	250887	63217386
Nail infection	32.28	22.40	16	20733	2507	63465766
Bone marrow infiltration	32.08	22.40	11	20738	673	63467600
Pericarditis	32.05	22.40	3	20746	131576	63336697
Lymphoedema	31.60	22.40	28	20721	11664	63456609
Hepatic function abnormal	31.55	22.40	49	20700	37093	63431180
Musculoskeletal stiffness	30.67	22.40	11	20738	184607	63283666
Therapeutic product effect decreased	29.65	22.40	13	20736	193174	63275099
Tumour haemorrhage	29.06	22.40	13	20736	1618	63466655
Varices oesophageal	28.94	22.40	16	20733	3132	63465141
Metastases to meninges	28.91	22.40	15	20734	2587	63465686
Hand dermatitis	28.79	22.40	8	20741	241	63468032
Biliary sepsis	28.77	22.40	11	20738	920	63467353
Intracranial pressure increased	28.49	22.40	19	20730	5208	63463065
Pulmonary mass	28.43	22.40	36	20713	22560	63445713
Transaminases increased	27.51	22.40	42	20707	31325	63436948
Arthritis	27.31	22.40	3	20746	115918	63352355
Extravasation	27.29	22.40	14	20735	2358	63465915
Central nervous system infection	27.26	22.40	10	20739	746	63467527
Left ventricular dilatation	27.23	22.40	9	20740	492	63467781
Cough	26.50	22.40	175	20574	292568	63175705
Maternal exposure during pregnancy	26.39	22.40	20	20729	220042	63248231
Poor peripheral circulation	26.34	22.40	16	20733	3733	63464540
Stomatitis	26.12	22.40	102	20647	138623	63329650
Product use in unapproved indication	26.02	22.40	13	20736	179067	63289206
Drug ineffective	26.00	22.40	218	20531	1044547	62423726
Device related infection	25.91	22.40	35	20714	23357	63444916
Paravenous drug administration	25.87	22.40	4	20745	3	63468270
Breast pain	25.65	22.40	22	20727	8776	63459497
Pleural neoplasm	25.64	22.40	8	20741	363	63467910
Therapeutic product effect incomplete	25.40	22.40	5	20744	125051	63343222
Intracranial tumour haemorrhage	25.38	22.40	7	20742	205	63468068
Anal erythema	25.38	22.40	7	20742	205	63468068
Skin toxicity	25.36	22.40	17	20732	4697	63463576
Seizure	25.36	22.40	98	20651	132536	63335737
Wound	25.03	22.40	11	20738	163252	63305021
Nail bed tenderness	24.87	22.40	8	20741	401	63467872
Mean cell haemoglobin concentration decreased	24.32	22.40	15	20734	3597	63464676
Toxicity to various agents	24.28	22.40	27	20722	247223	63221050
Asthma	24.09	22.40	6	20743	127555	63340718
Blood phosphorus decreased	23.82	22.40	16	20733	4437	63463836
Catheter site haemorrhage	23.47	22.40	14	20735	3161	63465112
Lymphocyte count decreased	23.06	22.40	38	20711	30219	63438054
Rectal haemorrhage	22.95	22.40	50	20699	48980	63419293
Fall	22.77	22.40	60	20689	392274	63075999
Scintillating scotoma	22.66	22.40	6	20743	150	63468123
Nail discolouration	22.64	22.40	13	20736	2737	63465536
Skin fissures	22.62	22.40	23	20726	11365	63456908
Bone pain	22.55	22.40	53	20696	54588	63413685
Odynophagia	22.40	22.40	19	20730	7467	63460806

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Paranasal sinus discomfort	59.16	49.68	10	408	830	34955683

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Disease progression	365.72	23.17	315	17723	184047	79542303
Metastases to central nervous system	340.27	23.17	131	17907	16244	79710106
Neuropathy peripheral	245.14	23.17	224	17814	141081	79585269
Ejection fraction decreased	226.86	23.17	124	17914	34453	79691897
Platelet count decreased	195.22	23.17	230	17808	194434	79531916
Metastases to lymph nodes	156.54	23.17	66	17972	10331	79716019
Thrombocytopenia	142.58	23.17	232	17806	265027	79461323
Metastases to lung	135.56	23.17	71	17967	18092	79708258
Epistaxis	117.02	23.17	135	17903	111380	79614970
Metastases to bone	108.33	23.17	68	17970	24359	79701991
Metastases to skin	96.13	23.17	29	18009	1710	79724640
Malignant neoplasm progression	95.73	23.17	135	17903	135855	79590495
Palmar-plantar erythrodysaesthesia syndrome	91.77	23.17	69	17969	33065	79693285
Myelosuppression	83.97	23.17	71	17967	40225	79686125
Constipation	72.55	23.17	182	17856	282868	79443482
Blood lactate dehydrogenase increased	71.49	23.17	64	17974	39106	79687244
Nodular regenerative hyperplasia	68.00	23.17	21	18017	1340	79725010
Cardiotoxicity	66.97	23.17	39	17999	12200	79714150
Left ventricular dysfunction	66.61	23.17	46	17992	19315	79707035
Drug interaction	66.42	23.17	8	18030	415175	79311175
Axillary pain	66.21	23.17	23	18015	2126	79724224
Metastases to liver	65.47	23.17	53	17985	28261	79698089
Neoplasm progression	65.28	23.17	69	17969	51613	79674737
Breast cancer metastatic	65.24	23.17	34	18004	8568	79717782
Blood uric acid decreased	64.88	23.17	20	18018	1268	79725082
Spider naevus	63.69	23.17	13	18025	145	79726205
Excessive eye blinking	63.39	23.17	21	18017	1680	79724670
Polyneuropathy	61.83	23.17	48	17990	24103	79702247
Aspartate aminotransferase increased	60.84	23.17	111	17927	138530	79587820
Eosinophil percentage increased	57.61	23.17	19	18019	1499	79724851
Nausea	53.91	23.17	385	17653	956811	78769539
Ejection fraction	53.78	23.17	20	18018	2249	79724101
Lymphoedema	53.63	23.17	34	18004	12379	79713971
Asthenopia	52.47	23.17	20	18018	2407	79723943
Diarrhoea	52.40	23.17	359	17679	880130	78846220
Nail dystrophy	52.17	23.17	16	18022	997	79725353
Alanine aminotransferase increased	51.92	23.17	114	17924	162456	79563894
Hyperchlorhydria	51.76	23.17	19	18019	2060	79724290
Radiation necrosis	50.30	23.17	13	18025	432	79725918
Joint swelling	50.23	23.17	4	18034	288642	79437708
Blood alkaline phosphatase increased	48.95	23.17	66	17972	63598	79662752
Vessel puncture site bruise	48.49	23.17	13	18025	499	79725851
Blood creatinine decreased	48.36	23.17	27	18011	7798	79718552
Vulvovaginal candidiasis	48.25	23.17	19	18019	2495	79723855
Tumour marker increased	47.74	23.17	22	18016	4250	79722100
Vascular device infection	46.54	23.17	29	18009	10247	79716103
Gamma-glutamyltransferase increased	45.61	23.17	59	17979	54621	79671729
Breast disorder	44.45	23.17	17	18021	2064	79724286
Recurrent cancer	43.57	23.17	18	18020	2675	79723675
Telangiectasia	42.69	23.17	15	18023	1434	79724916
Product dose omission issue	41.51	23.17	4	18034	247533	79478817
Toxicity to various agents	41.24	23.17	22	18016	421518	79304832
Drug hypersensitivity	40.56	23.17	9	18029	298907	79427443
Lymphangiosis carcinomatosa	40.36	23.17	16	18022	2138	79724212
Carcinoembryonic antigen increased	39.97	23.17	16	18022	2193	79724157
Portal hypertension	39.82	23.17	23	18015	7085	79719265
Non-cirrhotic portal hypertension	39.75	23.17	11	18027	476	79725874
Lacrimation increased	39.58	23.17	36	18002	22441	79703909
Hepatotoxicity	39.11	23.17	53	17985	51299	79675051
Gingival bleeding	38.75	23.17	31	18007	16245	79710105
Nail infection	38.69	23.17	16	18022	2383	79723967
Dry skin	38.48	23.17	61	17977	67934	79658416
Injection site extravasation	38.11	23.17	25	18013	9644	79716706
Nasopharyngitis	37.99	23.17	135	17903	253746	79472604
Hypertransaminasaemia	37.91	23.17	27	18011	11897	79714453
Hypothalamo-pituitary disorder	37.64	23.17	13	18025	1181	79725169
Hepatopulmonary syndrome	37.60	23.17	7	18031	46	79726304
Performance status decreased	37.52	23.17	21	18017	6092	79720258
Pituitary tumour	37.34	23.17	13	18025	1209	79725141
Gastrointestinal toxicity	37.01	23.17	23	18015	8086	79718264
Folate deficiency	36.60	23.17	17	18021	3343	79723007
Rheumatoid arthritis	35.95	23.17	3	18035	208467	79517883
Peripheral sensory neuropathy	35.76	23.17	27	18011	13006	79713344
Metastases to spine	35.41	23.17	18	18020	4306	79722044
Urinary tract infection	35.27	23.17	139	17899	274373	79451977
Hypokalaemia	35.14	23.17	91	17947	143949	79582401
Bone marrow infiltration	35.12	23.17	11	18027	735	79725615
Fatigue	34.11	23.17	340	17698	929387	78796963
Eastern Cooperative Oncology Group performance status worsened	34.08	23.17	14	18024	2051	79724299
Radiation pneumonitis	34.05	23.17	17	18021	3916	79722434
Cellulitis	33.14	23.17	75	17963	108985	79617365
Metastasis	32.64	23.17	20	18018	6860	79719490
Pneumonitis	32.26	23.17	53	17985	60807	79665543
Condition aggravated	31.84	23.17	40	17998	501084	79225266
Drug ineffective	31.49	23.17	132	17906	1080781	78645569
Cough	30.90	23.17	164	17874	366625	79359725
Acute kidney injury	30.42	23.17	44	17994	519360	79206990
Bone pain	30.16	23.17	49	17989	55693	79670657
Pulmonary mass	30.15	23.17	35	18003	28999	79697351
Weight decreased	30.05	23.17	159	17879	355039	79371311
Mucosal inflammation	30.00	23.17	58	17980	75522	79650828
Pleural effusion	29.68	23.17	86	17952	145176	79581174
Decreased appetite	29.46	23.17	154	17884	342264	79384086
Interstitial lung disease	29.40	23.17	73	17965	112527	79613823
Arteriovenous malformation	29.27	23.17	12	18026	1749	79724601
Poor peripheral circulation	29.20	23.17	15	18023	3668	79722682
Nail discolouration	28.92	23.17	14	18024	3017	79723333
Pleural neoplasm	28.61	23.17	8	18030	360	79725990
Hand dermatitis	28.25	23.17	8	18030	377	79725973
Hydrocephalus	27.94	23.17	20	18018	8880	79717470
Treatment failure	27.94	23.17	3	18035	170483	79555867
Seizure	27.87	23.17	100	17938	188734	79537616
Nail bed tenderness	27.68	23.17	8	18030	406	79725944
Breast pain	26.93	23.17	19	18019	8246	79718104
Biliary sepsis	26.81	23.17	11	18027	1606	79724744
Atrial fibrillation	26.75	23.17	6	18032	197880	79528470
Metastases to meninges	26.64	23.17	14	18024	3587	79722763
Breast cancer recurrent	26.16	23.17	13	18025	2964	79723386
Mean cell haemoglobin concentration decreased	26.14	23.17	15	18023	4564	79721786
Infusion related reaction	25.94	23.17	112	17926	230125	79496225
Dental fistula	25.70	23.17	8	18030	524	79725826
Central nervous system infection	25.00	23.17	10	18028	1367	79724983
Tumour haemorrhage	24.79	23.17	14	18024	4130	79722220
Stomatitis	24.51	23.17	81	17957	146676	79579674
Hormone receptor positive breast cancer	24.13	23.17	7	18031	360	79725990
Myocardial infarction	24.06	23.17	6	18032	184123	79542227
Spinal pain	23.92	23.17	23	18015	15369	79710981
Renal failure	23.60	23.17	8	18030	200960	79525390
Nasal dryness	23.54	23.17	14	18024	4549	79721801
Left ventricular dilatation	23.54	23.17	9	18029	1092	79725258
Vulvovaginal pain	23.48	23.17	11	18027	2204	79724146
Conjunctivitis	23.42	23.17	29	18009	25686	79700664
Blood phosphorus decreased	23.30	23.17	16	18022	6652	79719698

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L01FD03	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
MeSH PA	D050256	Antimitotic Agents
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D000074322	Antineoplastic Agents, Immunological
MeSH PA	D018796	Immunoconjugates
MeSH PA	D007155	Immunologic Factors
MeSH PA	D000922	Immunotoxins
MeSH PA	D009676	Noxae
MeSH PA	D050257	Tubulin Modulators

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
HER2-positive carcinoma of breast	indication	427685000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Receptor tyrosine-protein kinase erbB-2	Kinase	P04626	ERBB2_HUMAN	ANTIBODY BINDING				DRUG LABEL	DRUG LABEL
Tubulin beta	Tumour-associated antigen	P07437 Q9H4B7 Q13885 Q9BVA1 Q13509 P04350 P68371 Q9BUF5 Q3ZCM7	TBB5_HUMAN TBB1_HUMAN TBB2A_HUMAN TBB2B_HUMAN TBB3_HUMAN TBB4A_HUMAN TBB4B_HUMAN TBB6_HUMAN TBB8_HUMAN	INHIBITOR				DRUG LABEL	DRUG LABEL

External reference:

ID	Source
SE2KH7T06F	UNII
D09980	KEGG_DRUG
4032192	VUID
N0000186780	NUI
4032192	VANDF
C2935436	UMLSCUI
CHEMBL1743082	ChEMBL_ID
DB05773	DRUGBANK_ID
CHEMBL1201585	ChEMBL_ID
CHEMBL2109399	ChEMBL_ID
9295	INN_ID
6928	IUPHAR_LIGAND_ID
1371041	RXNORM
199194	MMSL
29308	MMSL
d08069	MMSL
014910	NDDF
702836004	SNOMEDCT_US
896752005	SNOMEDCT_US
D000080044	MESH_DESCRIPTOR_UI
CHEMBL2109484	ChEMBL_ID
168318470	PUBCHEM_CID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
KADCYLA	HUMAN PRESCRIPTION DRUG LABEL	1	50242-087	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	BLA	32 sections
KADCYLA	HUMAN PRESCRIPTION DRUG LABEL	1	50242-087	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	BLA	32 sections
KADCYLA	HUMAN PRESCRIPTION DRUG LABEL	1	50242-087	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	BLA	32 sections
KADCYLA	HUMAN PRESCRIPTION DRUG LABEL	1	50242-088	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	BLA	32 sections
KADCYLA	HUMAN PRESCRIPTION DRUG LABEL	1	50242-088	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	BLA	32 sections
KADCYLA	HUMAN PRESCRIPTION DRUG LABEL	1	50242-088	INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION	20 mg	INTRAVENOUS	BLA	32 sections